Siemens enters IVD market via $1.8 bil. DPC purchase
This article was originally published in The Gray Sheet
Executive Summary
Siemens will combine its medical imaging and healthcare IT business with Diagnostic Products Corporation's immunodiagnostic test offerings under a $1.86 bil. acquisition agreement slated for a DPC shareholder vote by June. Valued at $58.50 per share and announced April 27, the cash deal represents a roughly 21% premium over DPC's April 26 close of $48.45. The move will allow Siemens to establish a solid base in the cancer and cardiac disease testing markets. DPC, which will operate as a wholly owned subsidiary of Siemens, gains access to the German firm's broad distribution resources...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.